Effect of CKD and dialysis modality on exposure to drugs cleared by nonrenal mechanisms

American Journal of Kidney Diseases

Volumn 65, Issue 4, 2015, Pages 574-582

  Thomson, Benjamin K A ^a   Nolin, Thomas D ^b   Velenosi, Thomas J ^a   Feere, David A ^a   Knauer, Michael J ^a   Asher, Linda J ^a   House, Andrew A ^a,c   Urquhart, Bradley L ^a,c  

^a UNIVERSITY OF WESTERN ONTARIO   (Canada)

^b UNIVERSITY OF PITTSBURGH   (United States)

^c LAWSON HEALTH RESEARCH INSTITUTE   (Canada)

Author keywords

adverse effects; chronic kidney disease (CKD); CYP3A4; cytochrome P450; drug metabolism; hemodialysis (HD); hepatic and intestinal drug transporters; medication exposure.; Nonrenal drug clearance; peritoneal dialysis (PD); pharmacokinetics

Indexed keywords

CYTOCHROME P450 3A4; FEXOFENADINE; MIDAZOLAM; ANTIALLERGIC AGENT; ANXIOLYTIC AGENT; CYTOCHROME P450 3A; TERFENADINE;

ADULT; AREA UNDER THE CURVE; ARTICLE; CHRONIC KIDNEY DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; DIABETIC PATIENT; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG EXPOSURE; DRUG HALF LIFE; DRUG METABOLISM; FEMALE; GLOMERULUS FILTRATION RATE; GLUCOSE BLOOD LEVEL; HEMODIALYSIS; HUMAN; IN VIVO STUDY; KIDNEY FUNCTION; MALE; MAXIMUM PLASMA CONCENTRATION; MIDDLE AGED; PERITONEAL DIALYSIS; TIME TO MAXIMUM PLASMA CONCENTRATION; VOLUME OF DISTRIBUTION; AGED; ANALOGS AND DERIVATIVES; COMPARATIVE STUDY; KIDNEY; METABOLISM; RENAL INSUFFICIENCY, CHRONIC; RENAL REPLACEMENT THERAPY; SEVERITY OF ILLNESS INDEX; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTI-ALLERGIC AGENTS; ANTI-ANXIETY AGENTS; CYTOCHROME P-450 CYP3A; FEMALE; HUMANS; KIDNEY; MALE; MIDAZOLAM; MIDDLE AGED; PERITONEAL DIALYSIS; RENAL DIALYSIS; RENAL INSUFFICIENCY, CHRONIC; SEVERITY OF ILLNESS INDEX; TERFENADINE;

EID: 84926391147     PISSN: 02726386     EISSN: 15236838     Source Type: Journal    
DOI: 10.1053/j.ajkd.2014.09.015     Document Type: Article

References (49)

1. A.J. Collins, R.N. Foley, and C. Herzog US Renal Data System 2012 annual data report Am J Kidney Dis 61 1 suppl 1 2013 e1 e480
2. L. Neri, A. Martini, V.E. Andreucci, M. Gallieni, L.A. Rey, and D. Brancaccio Regimen complexity and prescription adherence in dialysis patients Am J Nephrol 34 1 2011 71 76
3. E. Chapin, M. Zhan, V.D. Hsu, S.L. Seliger, L.D. Walker, and J.C. Fink Adverse safety events in chronic kidney disease: the frequency of "multiple hits." Clin J Am Soc Nephrol 5 1 2010 95 101
4. T.D. Nolin, J. Naud, F.A. Leblond, and V. Pichette Emerging evidence of the impact of kidney disease on drug metabolism and transport Clin Pharmacol Ther 83 6 2008 898 903
5. T.J. Velenosi, A.Y. Fu, S. Luo, H. Wang, and B.L. Urquhart Down-regulation of hepatic CYP3A and CYP2C mediated metabolism in rats with moderate chronic kidney disease Drug Metab Dispos 40 8 2012 1508 1514
6. H. Sun, Y. Huang, L. Frassetto, and L.Z. Benet Effects of uremic toxins on hepatic uptake and metabolism of erythromycin Drug Metab Dispos 32 11 2004 1239 1246
7. J. Naud, J. Michaud, F.A. Leblond, S. Lefrancois, A. Bonnardeaux, and V. Pichette Effects of chronic renal failure on liver drug transporters Drug Metab Dispos 36 1 2008 124 128
8. C. Guevin, J. Michaud, J. Naud, F.A. Leblond, and V. Pichette Down-regulation of hepatic cytochrome P450 in chronic renal failure: role of uremic mediators Br J Pharmacol 137 7 2002 1039 1046
9. J. Michaud, T.D. Nolin, and J. Naud Effect of hemodialysis on hepatic cytochrome P450 functional expression J Pharmacol Sci 108 2 2008 157 163
10. T.D. Nolin, K. Appiah, S.A. Kendrick, P. Le, E. McMonagle, and J. Himmelfarb Hemodialysis acutely improves hepatic CYP3A4 metabolic activity J Am Soc Nephrol 17 9 2006 2363 2367
11. T.D. Nolin, and M.L. Unruh Clinical relevance of impaired nonrenal drug clearance in ESRD Semin Dial 23 5 2010 482 485
12. H. Sun, L. Frassetto, and L.Z. Benet Effects of renal failure on drug transport and metabolism Pharmacol Ther 109 1-2 2006 1 11
13. U.M. Zanger, and M. Schwab Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation Pharmacol Ther 138 1 2013 103 141
14. J. Michaud, J. Naud, and J. Chouinard Role of parathyroid hormone in the downregulation of liver cytochrome P450 in chronic renal failure J Am Soc Nephrol 17 11 2006 3041 3048
15. H. Sun, L.A. Frassetto, Y. Huang, and L.Z. Benet Hepatic clearance, but not gut availability, of erythromycin is altered in patients with end-stage renal disease Clin Pharmacol Ther 87 4 2010 465 472
16. Y. Zhang, L. Zhang, and S. Abraham Assessment of the impact of renal impairment on systemic exposure of new molecular entities: evaluation of recent new drug applications Clin Pharmacol Ther 85 3 2009 305 311
17. T.D. Nolin, R.F. Frye, and P. Le ESRD impairs nonrenal clearance of fexofenadine but not midazolam J Am Soc Nephrol 20 10 2009 2269 2276
18. Y.S. Lin, A.L. Dowling, and S.D. Quigley Co-regulation of CYP3A4 and CYP3A5 and contribution to hepatic and intestinal midazolam metabolism Mol Pharmacol 62 1 2002 162 172
19. S. Drescher, E. Schaeffeler, and M. Hitzl MDR1 gene polymorphisms and disposition of the P-glycoprotein substrate fexofenadine Br J Clin Pharmacol 53 5 2002 526 534
20. A.S. Levey, L.A. Stevens, and C.H. Schmid A new equation to estimate glomerular filtration rate Ann Intern Med 150 9 2009 604 612
21. European Renal Association-European Dialysis and Transplant Association. Section I. Measurement of renal function, when to refer and when to start dialysis Nephrol Dial Transplant 17 suppl 7 2002 7 15
22. National Kidney Foundation Hemodialysis Adequacy 2006 Work Group Clinical practice guidelines for hemodialysis adequacy, update 2006 Am J Kidney Dis 48 suppl 1 2006 S2 S90
23. National Kidney Foundation Peritoneal Dialysis 2006 Work Group Clinical practice guidelines for peritoneal dialysis adequacy Am J Kidney Dis 48 suppl 1 2006 S98 S129
24. P.E. Empey, T.M. Miller, A.H. Philbrick, J.A. Melick, P.M. Kochanek, and S.M. Poloyac Mild hypothermia decreases fentanyl and midazolam steady-state clearance in a rat model of cardiac arrest Crit Care Med 40 4 2012 1221 1228
25. M.F. Paine, D.D. Shen, and K.L. Kunze First-pass metabolism of midazolam by the human intestine Clin Pharmacol Ther 60 1 1996 14 24
26. P. Heizmann, M. Eckert, and W.H. Ziegler Pharmacokinetics and bioavailability of midazolam in man Br J Clin Pharmacol 16 suppl 1 1983 43S 49S
27. P. Heizmann, and W.H. Ziegler Excretion and metabolism of 14C-midazolam in humans following oral dosing Arzneimittelforschung 31 12a 1981 2220 2223
28. R. Vanholder, N. Van Landschoot, R. De Smet, A. Schoots, and S. Ringoir Drug protein binding in chronic renal failure: evaluation of nine drugs Kidney Int 33 5 1988 996 1004
29. R.K. Verbeeck, and F.T. Musuamba Pharmacokinetics and dosage adjustment in patients with renal dysfunction Eur J Clin Pharmacol 65 8 2009 757 773
30. G.R. Matzke, and T.J. Comstock Influence of Renal Function and Dialysis on Drug Disposition 4th ed. 2006 Lippincott Williams & Wilkins Philadelphia, PA
31. J.C. Gorski, S.D. Hall, D.R. Jones, M. VandenBranden, and S.A. Wrighton Regioselective biotransformation of midazolam by members of the human cytochrome P450 3A (CYP3A) subfamily Biochem Pharmacol 47 9 1994 1643 1653
32. M.D. Floyd, G. Gervasini, and A.L. Masica Genotype-phenotype associations for common CYP3A4 and CYP3A5 variants in the basal and induced metabolism of midazolam in European- and African-American men and women Pharmacogenetics 13 10 2003 595 606
33. H.R. Vinik, J.G. Reves, D.J. Greenblatt, D.R. Abernethy, and L.R. Smith The pharmacokinetics of midazolam in chronic renal failure patients Anesthesiology 59 5 1983 390 394
34. J.T. Backman, K.T. Olkkola, and P.J. Neuvonen Rifampin drastically reduces plasma concentrations and effects of oral midazolam Clin Pharmacol Ther 59 1 1996 7 13
35. K.T. Olkkola, J.T. Backman, and P.J. Neuvonen Midazolam should be avoided in patients receiving the systemic antimycotics ketoconazole or itraconazole Clin Pharmacol Ther 55 5 1994 481 485
36. M.S. Joy, R.F. Frye, and T.D. Nolin In vivo alterations in drug metabolism and transport pathways in patients with chronic kidney diseases Pharmacotherapy 34 2 2014 114 122
37. P.R. Keshaviah, K.D. Nolph, and J.C. Van Stone The peak concentration hypothesis: a urea kinetic approach to comparing the adequacy of continuous ambulatory peritoneal dialysis (CAPD) and hemodialysis Perit Dial Int 9 4 1989 257 260
38. D.C. Brater Drug dosing in patients with impaired renal function Clin Pharmacol Ther 86 5 2009 483 489
39. S. Gabardi, and S. Abramson Drug dosing in chronic kidney disease Med Clin North Am 89 3 2005 649 687
40. Y.W. Lam, S. Banerji, C. Hatfield, and R.L. Talbert Principles of drug administration in renal insufficiency Clin Pharmacokinet 32 1 1997 30 57
41. G.R. Matzke, G.R. Aronoff, and A.J. Atkinson Jr. Drug dosing consideration in patients with acute and chronic kidney disease-a clinical update from Kidney Disease: Improving Global Outcomes (KDIGO) Kidney Int 80 11 2011 1122 1137
42. M.Y. Munar, and H. Singh Drug dosing adjustments in patients with chronic kidney disease Am Fam Physician 75 10 2007 1487 1496
43. T.J. Velenosi, and B.L. Urquhart Pharmacokinetic considerations in chronic kidney disease and patients requiring dialysis Expert Opin Drug Metab Toxicol 10 8 2014 1131 1143
44. Top 100 drugs for 2013 by sales. http://www.drugs.com/stats/top100/2013/sales. Accessed April 11, 2013.
45. Lexi-Comp Online™. www.drugbank.ca. Hudson, OH: Lexi-Comp Inc; 2013. Accessed April 11, 2013.
46. DrugBank. Open Data Drug and Drug Target Database. 2013.
47. M. Dostalek, M.H. Court, B. Yan, and F. Akhlaghi Significantly reduced cytochrome P450 3A4 expression and activity in liver from humans with diabetes mellitus Br J Pharmacol 163 5 2011 937 947
48. J.H. Lee, A. Lee, J.H. Oh, and Y.J. Lee Comparative pharmacokinetic study of paclitaxel and docetaxel in streptozotocin-induced diabetic rats Biopharm Drug Dispos 33 8 2012 474 486
49. Guidance for Industry. Pharmacokinetics in patients with impaired renal function - study design, data analysis, and impact on dosing and labelling. 2010. http://www.fda.gov/downloads/Drugs/Guidances/UCM204959.pdf. Accessed April 11, 2013.